8-K: Aflac Reports Q4 2025 Earnings, Raises Dividend 5.2%

Aflac Incorporated announced solid fourth quarter and full year 2025 financial results, including a 0.6% increase in adjusted diluted EPS and a 5.2% dividend hike.

Summary

• Total revenues were $4.9 billion in the fourth quarter of 2025, a 9.9% decrease from $5.4 billion in Q4 2024.
• Net earnings for Q4 2025 were $1.4 billion, or $2.64 per diluted share, down from $1.9 billion, or $3.42 per diluted share, a year ago.
• Adjusted earnings in Q4 2025 were $818 million, a 5.4% decrease from $865 million in Q4 2024.
• Adjusted earnings per diluted share increased 0.6% to $1.57 in Q4 2025.
• For the full year 2025, total revenues were $17.2 billion, down 9.3% from $18.9 billion in 2024.
• Full year 2025 net earnings were $3.6 billion, or $6.82 per diluted share, compared with $5.4 billion, or $9.63 per diluted share, for 2024.
• Full year 2025 adjusted earnings were $4.0 billion, a 1.6% decrease from $4.1 billion in 2024.
• Full year 2025 adjusted earnings per diluted share increased 3.9% to $7.49.
• Aflac Japan's total new annualized premium sales increased 15.7% to 19.9 billion yen ($129 million) in Q4 2025, primarily driven by strong sales of the Miraito cancer insurance product.
• For the full year, Aflac Japan's sales increased 16.0% to 74.4 billion yen ($498 million).
• Aflac U.S. net earned premiums increased 4.0% to $1.5 billion in Q4 2025 and 2.9% to $6.0 billion for the full year.
• Aflac U.S. sales increased 3.1% in Q4 to $551 million, primarily benefiting from group voluntary products, and 3.0% to $1.6 billion for the full year.
• The board of directors declared a first quarter dividend of $0.61 per share, representing a 5.2% increase.
• Aflac repurchased $800 million in common shares (7.2 million shares) in Q4 2025 and $3.5 billion for the full year.
• Shareholders equity was $29.5 billion, or $56.85 per share, at December 31, 2025.
• Adjusted book value per share excluding foreign currency remeasurement increased 0.5%.
• The annualized adjusted return on equity excluding foreign currency remeasurement in Q4 was 14.5%.
• Aflac Japan's pretax adjusted profit margin for Q4 was 31.3%, a 30 basis point decrease year over year.
• Aflac U.S. pretax adjusted profit margin for Q4 was 17.4%, a 230 basis point decrease year over year.
• No charge-offs were recorded for the commercial real estate portfolio in Q4 2025.
• Charge-offs of $22 million were recorded on first lien senior secured middle market loans in Q4 2025.
• Adjusted leverage was 21.4% for the quarter, within the target range of 20% to 25%.
• The company ended the quarter with an SMR above 970% and an estimated regulatory ESR with the undertaking-specific parameter (USP) of 253%, with combined RBC estimated at 575%.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a solid performance, with strong operational metrics and capital management offsetting declines in GAAP net earnings largely due to investment gains fluctuations and currency impacts. The dividend increase and share repurchases reinforce shareholder value.

Positives

• Adjusted earnings per diluted share increased 0.6% to $1.57 in Q4 2025 and 3.9% to $7.49 for the full year 2025.
• Aflac Japan's quarterly sales increased 15.7% to 19.9 billion yen, primarily due to strong sales of the Miraito cancer insurance product.
• Aflac Japan's annual sales increased 16.0% to 74.4 billion yen.
• Aflac U.S. net earned premiums increased 4.0% in Q4 to $1.5 billion and 2.9% for the full year to $6.0 billion.
• Aflac U.S. sales increased 3.1% in Q4 to $551 million, benefiting from group voluntary products, and 3.0% to $1.6 billion for the full year.
• The board declared a first quarter dividend of $0.61 per share, a 5.2% increase, marking 43 consecutive years of dividend increases.
• Shareholders equity increased to $29.5 billion ($56.85 per share) at December 31, 2025, from $26.1 billion ($47.45 per share) a year ago.
• Adjusted book value per share excluding foreign currency remeasurement increased 0.5%.
• Strong capital ratios: SMR above 970%, estimated regulatory ESR with USP of 253%, and combined RBC of 575%.
• No charge-offs for the commercial real estate portfolio in Q4 2025.
• Deployed $800 million in capital to repurchase 7.2 million common shares in Q4, and $3.5 billion for the full year.
• Enhanced liquidity and capital flexibility by $2 billion with the creation of two off-balance sheet, pre-capitalized trusts (P-Caps).
• Unencumbered liquidity at the holding company stood at $4.1 billion, $3.1 billion above the minimum balance.

Negatives

• Total revenues decreased 9.9% in Q4 2025 to $4.9 billion and 9.3% for the full year to $17.2 billion.
• Net earnings decreased 27.5% in Q4 2025 to $1.4 billion and 33.0% for the full year to $3.6 billion.
• Net earnings per diluted share decreased 22.8% in Q4 2025 to $2.64 and 29.2% for the full year to $6.82.
• Adjusted earnings decreased 5.4% in Q4 2025 to $818 million and 1.6% for the full year to $4.0 billion.
• Net investment gains were significantly lower in Q4 2025 ($537 million) compared to Q4 2024 ($1.0 billion).
• Aflac Japan's net earned premiums in yen terms declined 1.9% in Q4 and 3.9% for the full year, mainly due to limited pay products reaching paid-up status.
• Aflac Japan's adjusted net investment income decreased 3.9% in yen terms in Q4 and 5.9% for the full year.
• Aflac Japan's pretax adjusted earnings in yen declined 3.5% in Q4 and 2.7% for the full year.
• Aflac U.S. pretax adjusted earnings decreased 9.1% in Q4 to $300 million, reflecting higher benefits and expenses.
• Aflac U.S. pretax adjusted profit margin decreased to 17.4% from 19.7% a year ago.
• Corporate and other segment reported a pretax adjusted loss of $31 million in Q4, compared to a loss of $4 million a year ago, due to higher business operations costs and interest expense.
• Variable investment income ran $12 million below long-term return expectations in Q4.
• Charge-offs of $22 million were recorded on first lien senior secured middle market loans in Q4.
• U.S. statutory recorded a $3 million valuation allowance on mortgage loans as an unrealized loss.
• Japan FSA booked a valuation allowance of 87 million yen related to transitional real estate loans.

Risks

• Difficult conditions in global capital markets and the economy, including inflation.
• Defaults and credit downgrades of investments.
• Global fluctuations in interest rates and exposure to significant interest rate risk.
• Concentration of business in Japan.
• Limited availability of acceptable Japanese yen-denominated investments.
• Foreign currency fluctuations in the yen/dollar exchange rate.
• Differing interpretations applied to investment valuations.
• Significant valuation judgments in determination of expected credit losses recorded on investments.
• Decreases in financial strength or debt ratings.
• Decline in creditworthiness of other financial institutions.
• Ability to attract and retain qualified sales associates, brokers, employees, and distribution partners.
• Deviations in actual experience from pricing and reserving assumptions.
• Ability to continue to develop and implement improvements in information technology systems and on successful execution of revenue growth and expense management initiatives.
• Interruption in telecommunication, information technology and other operational systems, or a failure to maintain the security, confidentiality, integrity or privacy of sensitive data residing on such systems, and uncertainty regarding the impact of the incident involving unauthorized access to the Company’s network in June 2025.
• Subsidiaries' ability to pay dividends to the Parent Company.
• Inherent limitations to risk management policies and procedures.
• Operational risks of third-party vendors.
• Tax rates applicable to the Company may change.
• Failure to comply with restrictions on policyholder privacy and information security.
• Extensive regulation and changes in law or regulation by governmental authorities.
• Competitive environment and ability to anticipate and respond to market trends.
• Catastrophic events, including, but not limited to, as a result of climate change, epidemics, pandemics, tornadoes, hurricanes, earthquakes, tsunamis, war or other military action, major public health issues, terrorism or other acts of violence, and damage incidental to such events.
• Ability to protect the Aflac brand and the Company's reputation.
• Ability to effectively manage key executive succession.
• Changes in accounting standards.
• Level and outcome of litigation or regulatory inquiries.
• Allegations or determinations of worker misclassification in the United States.

Future Outlook

For Aflac Japan in 2026, underlying earned premiums are expected to decline 1% to 2%. The benefit ratio is projected to be in the 60% to 63% range, the expense ratio in the 20% to 23% range, and the pretax profit margin in the 33% to 36% range. For Aflac U.S. in 2026, net earned premium growth is expected at the lower end of the 3% to 6% range. The benefit ratio is anticipated to be in the 48% to 52% range, the expense ratio in the 36% to 39% range, and the pretax profit margin in the 17% to 20% range.

Management Comments

• "Aflac delivered solid earnings for the quarter and the year. These results reflect our focused efforts to execute on our strategy of creating long-term value for shareholders." Daniel P. Amos, Chairman and CEO.
• "I am pleased with Aflac Japan's quarterly sales increase of 15.7% and annual sales increase of 16.0%. These strong results benefited largely from sales of our cancer insurance product Miraito." Daniel P. Amos.
• "Overall, I believe we are advancing the right strategy focused on sales of third sector products to new and younger customers to provide them with integrated financial protection and services throughout their different stages of life." Daniel P. Amos.
• "In the U.S., I continue to be encouraged by our ability to add $1.6 billion in new sales for the year, but more importantly, maintain strong persistency of 79.2%." Daniel P. Amos.
• "We treasure our 2025 milestone of 43 consecutive years of dividend increases and remain committed to extending this record, supported by our financial strength." Daniel P. Amos.
• "We intend to continue our balanced approach of investing in growth and driving long-term operating efficiencies." Daniel P. Amos.
• "For the fourth quarter of 2025, adjusted earnings per diluted share increased 0.6% year over year to $1.57, excluding effect of foreign currency in the quarter." Max Brodn, CFO.
• "Overall, we view these results in the quarter as solid." Max Brodn, CFO.
• "We have deliberately improved our ALM during this time, which has led to reduced exposure to interest rate risk." Max Brodn, CFO.
• "Given the strength of our capital and liquidity, we repurchased $800 million of our own stock and paid dividends of $303 million in Q4, offering good relative IRR on these capital deployments." Max Brodn, CFO.

Industry Context

StockSavvy.ai notes that Aflac's continued strong sales in Japan, particularly with new cancer insurance products like Miraito, demonstrate resilience in a mature market, aligning with broader trends of insurers adapting offerings to demographic shifts and health needs. The U.S. segment's focus on profitable growth through underwriting discipline and group voluntary products reflects a strategic response to competitive pressures and evolving employer benefits landscapes. The company's robust capital management and consistent dividend increases position it favorably against peers navigating volatile global markets and interest rate fluctuations.

Comparison to Industry Standards

• Aflac's 43 consecutive years of dividend increases significantly surpasses the average for S&P 500 companies, demonstrating exceptional financial stability and commitment to shareholder returns.
• The adjusted leverage ratio of 21.4% is well within the company's target range of 20-25%, indicating prudent financial management compared to industry peers who may face higher leverage in a rising interest rate environment.
• Capital ratios (SMR > 970%, ESR with USP 253%, Combined RBC 575%) are strong, suggesting a robust buffer against market volatility and credit cycles, potentially outperforming some competitors with less conservative capital structures.
• Aflac Japan's 15.7% Q4 sales growth for new annualized premiums, driven by cancer insurance, indicates strong product market fit and execution in a highly competitive and aging Japanese market, potentially outpacing local competitors in specific product lines.
• Aflac U.S. premium persistency of 79.2% is a strong indicator of customer retention, which is generally above industry averages for supplemental health insurance, reflecting effective customer service and product value.

Stakeholder Impact

• Shareholders: Positive impact due to increased dividend, share repurchases, and management's commitment to long-term value creation and extending the dividend increase record.
• Policyholders (Japan): Continued access to innovative products like Miraito and Anshin Palette, providing integrated financial protection.
• Policyholders (U.S.): Benefit from strong persistency and focus on profitable growth through underwriting discipline.
• Employees/Sales Associates/Brokers: Company's ability to attract and retain qualified sales associates, brokers, and employees is a risk factor, implying potential impact if not managed effectively.

Next Steps

• Promote Miraito, Tsumitasu, and Anshin Palette products in Japan in 2026.
• Continue prudent approach to expense management and maintaining a strong pretax margin in the U.S.
• Continue balanced approach of investing in growth and driving long-term operating efficiencies.
• Quarterly conference call via webcast on February 5, 2026.

Key Dates

Recommendation

Aflac's Q4 and full-year 2025 results show a mixed picture with strong operational performance in adjusted earnings and sales growth in key segments, particularly Japan, alongside declines in GAAP net earnings and total revenues. The significant dividend increase and ongoing share repurchases demonstrate a strong commitment to shareholder returns and robust capital management. However, the decline in net investment gains and the slight decrease in U.S. pretax profit margin warrant caution. The outlook for 2026 suggests continued strategic execution but with some expected declines in Japan's underlying earned premiums. Given the balance of positives and negatives, and the company's stable but not rapidly accelerating growth profile, a "hold" recommendation is appropriate for investors seeking consistent income and long-term stability, while acknowledging the impact of market fluctuations on reported GAAP figures.

Keywords

Aflac, Insurance, Financial Results, Earnings, Dividend, Share Repurchase, Japan Insurance, US Insurance, Supplemental Health Insurance, Cancer Insurance, Medical Insurance, Adjusted Earnings, Shareholders Equity, Capital Management, Risk Management, SEC Filing, 8-K